← Home / Immunome, Inc. (IMNM)
Stock Analysis
Immunome, Inc. (IMNM)
IMNM
IMNM · Healthcare • Biotech
23.08 -0.13%
Track IMNM in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when IMNM price is:
52W Range Position
78%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-07-31 11:45 UTC
WOI Investment Thesis
Constructive
Confirmation improves above 26.97. Holding above 21.87 keeps the current thesis intact.
⚖️
✓
Fundamentals
Weak / Insufficient
✓
Price Structure
Constructive
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
21.87
↗
Break Above
Confirmation improves above resistance.
26.97
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below 21.87
Recent Company Events
SEC VERIFIED
Latest material filings
MAY
12
●
Financial Results
HIGH
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026 • New Drug Application (NDA) submitted to the U.S.
8-K Filing • SEC EDGAR
What's Driving IMNM?
📈 Technical recovery is improving
Momentum is Neutral. Watch 26.97 for confirmation and 21.87 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
Below 21.87
Full Analysis Workspace
Technical Signal
Technical Setup Active
✓
An active technical structure is present. Use trigger, target, stop and watch levels for context.
Pattern
Triangle Compression / ASC / DOWN
State
Forming
Downtrend Structure
Downtrend line not broken yet · score 2
Trigger
24.57
Invalidation
24.57
Compression
87%
◎
How to read this setup
The nearest decision zone is framed by support around 21.87 and resistance near 24.57. A cleaner push through resistance would improve continuation odds, while a loss of support would weaken the current thesis.
Price Chart
IMNM — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-30
Spec
Speculative premium
Valuation is very demanding relative to current fundamentals; expectations are high.
Market Cap
$2.6B
Company size
EV
$2.0B
Debt-adjusted value
P/E
-11.6
Not meaningful
P/B
4.4
Balanced
EV/EBIT
-8.5
Not meaningful
P/FCF
-12.7
Not meaningful
FCF Yield
-7.87%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial context is mixed
Financial conditions require selective monitoring.
↗
Revenue Growth
Weak
●
Profitability
Insufficient
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
0.00
↘ Weak
📈 Net Income
-53.84M
≈ Insufficient
🧮 EPS (Basic)
-0.48
≈ Insufficient
Immunome, Inc.
Healthcare • Biotech
Related Opportunities